{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:47:40Z","timestamp":1784616460370,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clear cell renal cell carcinoma (ccRCC or KIRC) is a malignant neoplasm characterized by reprogrammed lipid metabolism. Fatty acid desaturase 3 (FADS3), a sphingoid \u039414Z desaturase, is required for the synthesis of unsaturated fatty acids in tumor biology. However, the role of FADS3 in ccRCC progression and prognosis and in modulating the tumor immune microenvironment (TIME) remains to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ccRCC transcriptomic datasets were obtained from the TCGA, GEO, and GTEx databases. Mendelian randomization (MR) and single-cell RNA sequencing analyses were used to investigate the associations of FADS3 with lipid metabolism, and differential expression genes in ccRCC. Bioinformatics analysis was also used to investigate the association of FADS3 expression with tumor progression, prognosis, TIME, and potential pathogenic mechanism in ccRCC. FADS3 expression in ccRCC cell lines was confirmed by qRT-PCR, western blotting, RNA-Seq. FADS3 roles in ccRCC were assessed by functional assays including cell proliferation, migration, invasion, and colony formation using wild-type and FADS3-knockdown cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lipid metabolism was found to be upregulated in ccRCC tumor tissues based on comprehensive bioinformatic analysis. FADS3 was among the upregulated genes associated with lipid metabolism, which was expressed not only in ccRCC tumor cells but also in cells of the TIME, such as tumor-associated macrophages (TAMs). High FADS3 expression remodeled the TIME and predicted poor prognosis in ccRCC. Functional assays demonstrated that FADS3 knockdown markedly suppressed ccRCC cell proliferation, migration and invasion. Transcriptomic analyses further suggested that FADS3 may promote ccRCC progression through activation of oncogenic and metabolic signaling pathways, such as the PI3K\/Akt pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FADS3 is a lipid metabolism-associated oncogenic driver in ccRCC, and its upregulation remodels the TIME and predicts poor prognosis. FADS3 may represent a potential therapeutic target for ccRCC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1817492","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:15Z","timestamp":1778733015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive analysis of fatty acid desaturase 3 in clear cell renal cell carcinoma: insights into tumor progression, immune microenvironment, and clinical outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Si-Tao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, Jiangnan University Medical Center","place":["Wuxi, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan-Rui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]},{"name":"MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jun","family":"Ge","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]},{"name":"MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Health and Medicine, Wuxi Taihu University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Sheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]},{"name":"MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Han","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Jiangnan University Medical Center","place":["Wuxi, China"]},{"name":"Wuxi School of Medicine, Jiangnan University","place":["Wuxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.727778","article-title":"The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1195500","article-title":"Metabolic reprogramming of clear cell renal cell carcinoma","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An integrated metabolic atlas of clear cell renal cell carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-14-1507","article-title":"HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma","volume":"5","author":"Qiu","year":"2015","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-21-0211","article-title":"Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma","volume":"11","author":"Riscal","year":"2021","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.103032","article-title":"HIF-2alpha\/LPCAT1 orchestrates the reprogramming of lipid metabolism in ccRCC by modulating the FBXW7-mediated ubiquitination of ACLY","volume":"21","author":"Fei","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000004094","article-title":"FADS3 fuels ccRCC progression via lipid-droplet\/TGF-\u03b2 receptors axis bridging metabolic reprogramming and epithelial plasticity","volume":"112","author":"Sun","year":"2025","journal-title":"Int J Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-3249","article-title":"Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"19","author":"von Roemeling","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41419-025-07782-y","article-title":"PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-1023","article-title":"Inactivation of the AMPK-GATA3-ECHS1 pathway induces fatty acid synthesis that promotes clear cell renal cell carcinoma growth","volume":"80","author":"Qu","year":"2020","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","article-title":"Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors","volume":"21","author":"Burgers","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12967-023-04161-z","article-title":"Fatty acids metabolism affects the therapeutic effect of anti-PD-1\/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma","volume":"21","author":"Lin","year":"2023","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12943-025-02457-w","article-title":"Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting","volume":"24","author":"Deng","year":"2025","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/nu8010023","article-title":"Fatty acid desaturases, polyunsaturated fatty acid regulation, and biotechnological advances","volume":"8","author":"Lee","year":"2016","journal-title":"Nutrients"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.biochi.2010.03.002","article-title":"Fatty acid desaturase 3 (Fads3) is a singular member of the Fads cluster","volume":"93","author":"Blanchard","year":"2011","journal-title":"Biochimie"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gene.2009.06.016","article-title":"Novel fatty acid desaturase 3 (FADS3) transcripts generated by alternative splicing","volume":"446","author":"Park","year":"2009","journal-title":"Gene"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC119.011883","article-title":"FADS3 is a \u039414Z sphingoid base desaturase that contributes to gender differences in the human plasma sphingolipidome","volume":"295","author":"Karsai","year":"2020","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902645R","article-title":"Biosynthesis of the anti-lipid-microdomain sphingoid base 4,14-sphingadiene by the ceramide desaturase FADS3","volume":"34","author":"Jojima","year":"2020","journal-title":"FASEB J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101936","article-title":"Roles and therapeutic targeting of ceramide metabolism in cancer","volume":"83","author":"Wajapeyee","year":"2024","journal-title":"Mol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13046-022-02259-8","article-title":"Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients","volume":"41","author":"Fina","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111437","article-title":"Integrative analysis of FADS3 as a marker for prognosis and immunity in head and neck squamous cell carcinoma","volume":"124","author":"Tang","year":"2024","journal-title":"Cell Signal"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582887","article-title":"Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M042572","article-title":"Trans-vaccenate is \u039413-desaturated by FADS3 in rodents","volume":"54","author":"Rioux","year":"2013","journal-title":"J Lipid Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2023.159335","article-title":"Metabolism of sphingadiene and characterization of the sphingadiene-producing enzyme FADS3","volume":"1868","author":"Jojima","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00911-z","article-title":"Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis","volume":"19","author":"Lau","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1116839","article-title":"Exploring the role of sphingolipid-related genes in clinical outcomes of breast cancer","volume":"14","author":"Pei","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp Mol Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1074242","article-title":"Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008811","article-title":"Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105259","article-title":"Fatty acid metabolic reprogramming in gastrointestinal tumor microenvironment: emerging mechanisms and therapeutic opportunities","volume":"222","author":"Sun","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.ircmb.2024.07.003","article-title":"Tumor microenvironment induced switch to mitochondrial metabolism promotes suppressive functions in immune cells","volume":"389","author":"Pandey","year":"2024","journal-title":"Int Rev Cell Mol Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188962","article-title":"Intratumoral lipid metabolic reprogramming as a pro-tumoral regulator in the tumor milieu","volume":"1878","author":"Wang","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1644645","article-title":"Exosomal FABP5 drives HCC progression via macrophage lipid metabolism and immune microenvironment remodeling","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2000446","article-title":"EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy","volume":"2","author":"Guo","year":"2009","journal-title":"Sci Signal"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(01)00623-9","article-title":"Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells","volume":"62","author":"Zhuang","year":"2002","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.415","article-title":"Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes","volume":"130","author":"Calay","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216681","article-title":"Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC","volume":"586","author":"Bullock","year":"2024","journal-title":"Cancer Lett"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333492","article-title":"Induction of macrophage efferocytosis in pancreatic cancer via PI3Kgamma inhibition and radiotherapy promotes tumour control","volume":"74","author":"Russell","year":"2025","journal-title":"Gut"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1817492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:23Z","timestamp":1778733023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1817492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1817492"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1817492","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1817492"}}